Expect ADC market to double
- A new market report says the antibody-drug conjugate sector will rise to $32.66 billion by 2035, from $14.76 billion in 2026. - The forecast implies 9.23% annual growth as drugmakers expand targeted cancer medicines and suppliers scale the antibodies, linkers and toxic payloads. - Filtration demand is rising alongside biologics manufacturing and sterility rules. (marketsandmarkets.com)
Antibody-drug conjugates are cancer medicines built like guided missiles: an antibody finds a tumor cell, then delivers a toxic payload. (fda.gov) A market report published April 28 said the global antibody-drug conjugate market is projected to grow from $14.76 billion in 2026 to $32.66 billion by 2035, a 9.23% compound annual growth rate. (finance.yahoo.com) (towardshealthcare.com) That forecast sits on top of a fast-moving commercial backdrop. The Food and Drug Administration approved Enhertu with pertuzumab on December 15, 2025, for first-line HER2-positive metastatic breast cancer. (fda.gov) (astrazeneca.com) For drugmakers, the hard part is not just inventing an antibody-drug conjugate. It is manufacturing a sterile biologic, attaching the linker and payload consistently, and proving the final product is contamination-free. (fda.gov) (bioprocessintl.com) That is where microfiltration comes in. The membranes act like ultra-fine sieves that remove particles and microbes from process fluids without damaging sensitive biologic material. (marketsandmarkets.com) (reportsnreports.com) MarketsandMarkets said the pharmaceutical microfiltration market was worth $6.13 billion in 2025 and could reach $9.94 billion by 2030, growing 10.1% annually. (marketsandmarkets.com) Those two forecasts are linked by the same factory economics. More biologics and more sterile injectables mean more validated filters, more single-use assemblies, and more quality-control testing. (marketsandmarkets.com) (reportsnreports.com) The numbers should still be read carefully because they come from commercial market-research firms, and rival reports give different totals for the antibody-drug conjugate market in 2035. Precedence Research pegs it at $34.80 billion, while Roots Analysis puts 2035 at $28.41 billion. (precedenceresearch.com) (rootsanalysis.com) What is consistent across those reports is direction, not precision: antibody-drug conjugates are expanding, and the manufacturing tools around them are growing with them. (finance.yahoo.com) (marketsandmarkets.com)
